Xidian Pharmaceutical: Shareholders intend to reduce their stake by no more than 3% of the company's shares.

West Point Pharma announced that its shareholder, Hengqin Dingdian Equity Investment Fund Partnership Enterprise, which holds more than 5% of the company's shares, and its concerted action person, Zhuhai Hengqin Runhuiyi Investment Partnership Enterprise, plan to reduce their holdings by a cumulative total of no more than 2,294,700 shares, which is no more than 3% of the total share capital of the company.